 Decibel Therapeutics Inc NASDAQ: DBTX reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. The interim analysis showed that 88 of. 